Pro Medicus (ASX:PME) share price in focus after broker upgrade

The Pro Medicus Limited (ASX: PME) share price has been a strong performer in 2021.

Since the start of the year, the health imaging company’s shares have rallied an impressive 27% higher.

This means the Pro Medicus share price has now doubled in value over the last 12 months.

Is it too late to buy Pro Medicus shares?

The good news for investors is that it may not be too late to buy Pro Medicus shares.

According to a note out of Goldman Sachs this morning, the broker has upgraded its shares to a buy rating with a $53.80 price target.

This price target implies potential upside of approximately 20% over the next 12 months.

Why is Goldman Sachs bullish on Pro Medicus?

Goldman has been impressed with the way the company continues to